Kirgen Bioscience (Shanghai) Co., Ltd., a leading enterprise of high-end laboratory consumables and new materials in China, announced the completion of a new round of financing of nearly 100 million yuan. This round of financing was led by Xingsheng Capital and jointly participated by Yida Capital and Yaojin Capital. This round of financing will be used for KIRGEN Biology's continuous investment in R & D in the field of high-end laboratory consumables and stuck neck cell culture new materials, the expansion of high-end laboratory consumables production base and the market promotion of related products.

Located in Zhangjiang, Kirgen Bioscience (Shanghai) Co., Ltd.  is a high-tech enterprise committed to the research and development of imported monopoly "bottleneck" high-end laboratory consumables and underlying innovative materials. At present, the company's main products are liquid treatment, molecular biology and high-end laboratory consumables and membrane materials for cell storage and culture, mainly used in basic scientific research, in vitro diagnosis, vaccines, cell therapy, antibody drugs, gene therapy and other biopharmaceutical related fields. The company has the ability to layout the whole industry chain from raw material research and development, polymer material modification and coating, and high-quality production and sales of high-end products. Its products have entered the procurement system of many top pharmaceutical enterprises and CXO enterprises, and it is a leading enterprise of high-end laboratory consumables in China.

The top-level technology tackles the "stuck neck" material barriers and production processes

KIRGEN successfully broke the monopoly of overseas developed countries in the formulation of molecular materials and modification package in the field of molecular biology and cell biology. In the field of high-end molecular biology and laboratory consumables for cell biology, the important process of polymer material formulation and subsequent modification processing are the core technical barriers. At present, the domestic high-end product market is mainly monopolized by corning, Thermo fly, Saidolis, Ebender and other foreign life science leading enterprises.The high price and long delivery cycle have become the key areas restricting the rapid development of China's biopharmaceutical industry.

Branch into biological since the date of establishment based on the underlying technology, accumulate and strictly control production process, successfully developed including a new generation of automated liquid processing consumables, biological bag membrane material, high-end cell culture consumables, and many other high-end products, become the current scientific research, biological pharmaceutical and in vitro diagnosis of China's few can achieve successful research and development and mass production enterprises, and has begun to carry out sales promotion. The modification of polymer raw materials, the independent production process formula, the production process with fully independent intellectual property rights, and the establishment of scientific automatic production line have built a solid competition barrier for KIRGEN biology.

Pay attention to the production technology, adhering to the spirit of craftsmanship

The company has long attached great importance to the optimization of production process and quality control in the production process, and the products have been recognized and favored by many foreign pharmaceutical enterprises and listed companies in the pharmaceutical industry, and have successfully entered the procurement system of high-quality customers. With the rapid development and maturity of China's biopharmaceutical industry, the market scale of biopharmaceutical and in vitro diagnosis will continue to expand. With the spirit of craftsmanship for many years, KIRGEN Biology will always play the mission of high-quality domestic national brand, and help the vigorous development of China's bio-pharmaceutical industry with the best quality products.

Regarding the success of this financing, Mr.Zhu Yiming, chairman of KIRGEN Biology, said: for a long time, KIRGEN Biology has always been providing high-quality laboratory consumables products for the domestic life science field, and will spare no effort for Chinese enterprises in the field of molecular biology and cell biology. We are very grateful for the recognition of the company by Xingzheng Capital, the high-quality investment institutions in the big health industry, and Yida Capital, and also very grateful for the continuous support of the strategic shareholder Sinopharm Holding Yaojin Capital. We will continue to uphold the corporate philosophy of "surpassing ourselves, pursuing excellence", carry forward the national brand, and provide the best quality products for Chinese partners in the field of life science.

Xing capital vice President Xiang Jun said: the rise of China's life science industry drives the rapid development of upstream experimental consumables industry, families into biological as life science experiment consumables industry leading enterprises, relying on independent research and development of core technology, built a series of laboratory high-end consumables products matrix, for China's life science industry innovation and development and experimental consumables supplies security to provide strong support and security. We believe that under the leadership of the company's management team, KIRGEN Biology will accelerate the development of high-end products, core technologies, domestic and overseas markets, and continue to lead the industry. Xingsheng Capital will continue to play its professional advantages to help enterprises grow.

Huang Liqun, partner of Yida Capital, said: With the overall rapid development of China's pharmaceutical industry and the continuous increase in the number and investment of clinical trials, the market demand for biological experimental consumables will continue to expand in the future, and domestic brands are gradually realizing import substitution. As the head brand of domestic laboratory consumables, KIRGEN Biotech has innovatively made a breakthrough in the raw material end of biological experimental consumables, and is expected to realize the localization of key materials of "stuck neck" in China. Yida Capital will continue to help KIRGEN biology to become bigger and stronger.

Mr.Li Ke, general manager of Yaojin Capital, said: I am very glad to see KIRGEN Capital completed this round of financing. As a strategic shareholder of Kojin Capital, Yaojin Capital continues to support KIRGEN Biology, helping it to promote the completion of technical breakthroughs in key fields. High-end laboratory consumables quality is closely related to research and development results, the development of domestic enterprises in the field and overseas giants always has a large technology gap, hope families into biological as production of "small, fine, special, designed" the leading brand, can keep research and development investment and expand the product portfolio, provide downstream high quality domestic products.